2496 — Wuhan YZY Biopharma Co Cashflow Statement
0.000.00%
Last trade - 00:00- HK$800.60m
- HK$832.12m
- CNY66.86m
Annual cashflow statement for Wuhan YZY Biopharma Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | — |
| Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | fx Preliminary |
| Net Income/Starting Line | -149 | -189 | -192 | -97.6 | — |
| Depreciation | |||||
| Non-Cash Items | 53.8 | 3.15 | 1.72 | 0.144 | — |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -11.5 | 2.12 | -3.31 | -9.79 | — |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -98.7 | -177 | -186 | -101 | — |
| Capital Expenditures | -1.9 | -1.41 | -1.93 | -1.51 | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -18 | 7.21 | 56.7 | -3.16 | — |
| Sale of Fixed Assets | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -19.9 | 5.8 | 54.8 | -4.67 | — |
| Financing Cash Flow Items | -4.39 | -6.73 | -9.88 | -4.08 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 81 | 241 | 176 | 33 | — |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -37.6 | 70.4 | 43.2 | -70.4 | — |